{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Bush administration officials say they have become deeply concerned that a cut in Medicare payments to doctors, to be announced next week, will prompt many doctors to limit their participation in the program, reducing access to health care for the elderly. Medicare payments to doctors were cut 5.4 percent in January, and Medicare officials said that next week they expected to announce a further cut of 4.4 percent, effective on Jan. 1.", "headline": {"main": "Lower Medicare Payouts Concern Bush Officials"}, "abstract": "Bush administration officials say they are deeply concerned that upcoming cut in Medicare payments to doctors will prompt many practitioners to limit their participation in the program, reducing access to health care for elderly; say administration has no discretion to halt cuts, which result from formula specified in Medicare law; contention is disputed by some doctors and lawmakers (M)", "print_page": "16", "word_count": 1080, "_id": "4fd21ffd8eb7c8105d7a32dd", "snippet": "Bush administration officials say they have become deeply concerned that a cut in Medicare payments to doctors, to be announced next week, will prompt many doctors to limit their participation in the program, reducing access to health care for the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/10/25/us/lower-medicare-payouts-concern-bush-officials.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2002-10-25T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The Bristol-Myers Squibb Company said yesterday that it would restate its financial results to reflect its retreat from controversial inventory practices. The company also said third-quarter sales were hurt by competition from generic drug makers. Bristol-Myers said final results for the period would be delayed until it completed the restatement, which is expected to increase sales and earnings for 2002 and lower them for previous years, primarily 2000 and 2001. The restatement will affect more than $2 billion in sales and 61 cents of earnings per share.", "headline": {"main": "Bristol-Myers to Restate Results to Reflect Shift in Inventory Policy"}, "abstract": "Bristol-Myers Squibb Co says it will restate its financial results to reflect its retreat from controvesial inventory practics; also says third-quarter sales were hurt by competition from generic drug makers; says final results for period will be delayed until it completes restatement, which is expected to increase sales and earnings for 2002 and lower them for previous years, primarily 2000 and 2001; restatement will affect for more than $2 billion in sales; restatement comes as federal regulators are reviewing whether company improperly inflated revenue by giving wholesalers incentives to buy excessive amounts of products; chairman-chief executive Peter R Dolan emphasizes that company has worked off more than 75 percent of its excess inventory and should work off more than 90 percent by end of year; company reports quarterly sales of $4.2 billion, down 12 percent from year earlier; earnings fell 75 percent, to $314 million from $1.245 billion year ago; company remains under formal investigation by Securities and Exchange Commission (M)", "print_page": "2", "word_count": 708, "_id": "4fd289048eb7c8105d85a73d", "snippet": "The Bristol-Myers Squibb Company said yesterday that it would restate its financial results to reflect its retreat from controversial inventory practices. The company also said third-quarter sales were hurt by competition from generic drug makers.   ...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/10/25/business/bristol-myers-to-restate-results-to-reflect-shift-in-inventory-policy.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "DOLAN, PETER R"}, {"name": "organizations", "value": "SECURITIES AND EXCHANGE COMMISSION"}, {"name": "organizations", "value": "BRISTOL-MYERS SQUIBB CO"}, {"name": "subject", "value": "SALES"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "COMPANY REPORTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Reed", "lastname": "ABELSON"}], "original": "By REED ABELSON"}, "document_type": "article", "pub_date": "2002-10-25T00:00:00Z", "section_name": "Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "President Bush today proposed a way to speed the approval of low-cost generic versions of prescription drugs, and consumer groups lauded the proposal as a worthy first step, although they said it was too late and did not go far enough. At least as significant as the details of Mr. Bush's announcement was the fact that he joined a chorus of critics who say makers of brand-name drugs have staved off generic competition by improperly manipulating drug and patent laws.", "headline": {"main": "Bush Seeks Faster Generic Drug Approval"}, "abstract": "Pres Bush proposes to speed approval of low-cost generic versions of prescription drugs through FDA rules that would limit companies' ability to delay or block sale of generics; consumer groups laud first step but question why Bush did not express such views when Senate debated drug legislation; bill was approved by Senate but not yet by House; Sen Charle Schumer suspects 'Election Day conversion' (M)", "print_page": "24", "word_count": 998, "_id": "4fd2207f8eb7c8105d7a41dc", "snippet": "President Bush today proposed a way to speed the approval of low-cost generic versions of prescription drugs, and consumer groups lauded the proposal as a worthy first step, although they said it was too late and did not go far enough.    At least as...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/10/22/us/bush-seeks-faster-generic-drug-approval.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "SCHUMER, CHARLES E"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2002-10-22T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "Mifepristone, once called RU-486, is best known as the abortion pill. But some scientists believe that the drug may eventually serve another, far less controversial, purpose: treating a particularly fierce and intractable form of depression.", "headline": {"main": "Abortion Pill May Help Treat Severe Form of Depression"}, "abstract": "Corcept Therapeutics psychiatrist and chief executive Dr Joseph Belankoff, in article published in journal Biological Psychiatry, reports finding that mifepristone, abortion pill once called RU-486, is effective in helping people with severe depression accompanied by delusional beliefs or hallucinations; company applies to Food and Drug Administration for approval to market drug for psychotic depression; photo (M)", "print_page": "5", "word_count": 909, "_id": "4fd23cf58eb7c8105d7d2d40", "snippet": "Mifepristone, once called RU-486, is best known as the abortion pill.    But some scientists believe that the drug may eventually serve another, far less controversial, purpose: treating a particularly fierce and intractable form of depression.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/10/22/health/abortion-pill-may-help-treat-severe-form-of-depression.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BELANKOFF, JOSEPH"}, {"name": "organizations", "value": "CORCEPT THERAPEUTICS"}, {"name": "subject", "value": "MIFEPRISTONE (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Erica", "lastname": "GOODE"}], "original": "By ERICA GOODE"}, "document_type": "article", "pub_date": "2002-10-22T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 4, "offset": 0, "time": 43}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}